RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Roche Venture Fund
R

Roche Venture Fund portfolio

Roche Venture Fund has 2 portfolio companies on record at Recent Funding. It led 1 of the 3 rounds it joined. Its most recent investment on record is Splice Bio's $140M Series B+ round in June 2025, alongside Ysios Capital, UCB Ventures, Sanofi Ventures and 5 others. By category, its portfolio leans toward Health and bio (2). It has co-invested with Sofinnova Partners, NEA and Sanofi Ventures, most often Sofinnova Partners (2 rounds).

Type: Investor.
Portfolio on Recent Funding: 2.
Deals, last 12 months: 0.
Rounds led: 1 of 3.
Capital in their rounds: $319M.
Latest deal: Splice Bio · Jun 11, 2025.

What Roche Venture Fund invests in

Roche Venture Fund recent investments

CompanyRoundDateAlongside
SSplice BioSeries B+ · $140MYsios Capital, UCB Ventures, Sanofi Ventures (lead) +5
GGlycoEraSeries B+ · $130MSofinnova Partners, Sixty Degree Capital, Qatar Investment Authority +6
GGlycoEraSeries A · $49M · leadSofinnova Partners (lead), LimmaTech Biologics, 5AM Ventures (lead)

How Roche Venture Fund invests

StageDealsCapital in rounds
Series B+ 2 67%$270M
Series A 1 33%$49M
YearDealsCapital in rounds
2021 1 33%$49M
2025 2 67%$270M

Share is of the 3 rounds on Recent Funding that name Roche Venture Fund. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Roche Venture Fund portfolio companies

CompanyRound with Roche Venture FundTotal raisedLatest raise
SSplice Bio
Health and bio
Series B+ · $140M$197MJun 11, 2025
Series B+
GGlycoEra
Health and bio
Series B+ · $130M$179MMay 27, 2025
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

Portfolio companies are the companies on Recent Funding with a round that lists Roche Venture Fund, which is a subset of its real portfolio. API: /api/v1/investors/roche-venture-fund (get a free API key). More: the most active VC firms and new venture capital funds.